Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.52 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17361073 | 0.99 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4671370 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL12154791 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL9372786 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| Hydrochloric Acid SCHEMBL28852374 | 0.88 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL458805 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL15140566 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL2527774 | 0.87 | HTT (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL22284271 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL1069985 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104154-A1 | 5-[2,7-DIAZASPIRO[3.5]NONAN-7-YL]-5-[4-PHENOXYPHENYL]HEXAHYDROPYRIMIDINE-2,4,6-TRIONE DERIVATIVES AS MMP9 INHIBITORS FOR THE TREATMENT OF DRY EYE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025015167-A2 | ERASTIN KETONE ANALOGS AND USES THEREOF | EXARTA THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119306698-A | Novel method for preparing zavigpam intermediate | 浙江工业大学 | 2025-01-14 | — | — | CN | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-5741792-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0623596-A1 | N-acylpyrrolidines or N-acylpiperidines having a guanidinyl- or amidinyl-substituted side chain as thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-09 | — | — | EP | disclosed |
| US-4433150-A | HYPNBOTICS, ANTICONVULSANTS, TRANQUILIZERS, ANTIDEPRESSANTS, SEDATIVES, ANTIARRHYTHMIA AGENTS | PHARMINDUSTRIE (FR) | 1984-02-21 | — | — | US | disclosed |
| EP-0031753-A1 | 2-(4-Piperidyl)-1-(4-quinolyl)-ethanone derivatives, intermediates in and process for their preparation, and their use as medicines | PHARMUKA LABORATOIRES (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SMN1; SMN2 2622/4885NPC1 3887/4885RAB9A 2985/4885 |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | SLC18A2, SLC6A2, SLC18A1 | SMN1; SMN2 634/4885NPC1 201/4885RAB9A 326/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SMN1; SMN2 2298/4885NPC1 859/4885RAB9A 876/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | SMN1; SMN2 2425/4885NPC1 157/4885RAB9A 655/4885 |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | SLC18A2, SLC6A2, SLC18A1 | SMN1; SMN2 634/4885NPC1 201/4885RAB9A 326/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | SMN1; SMN2 2425/4885NPC1 157/4885RAB9A 655/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | SMN1; SMN2 2622/4885NPC1 3887/4885RAB9A 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.